Treatment for Hemophilia A Approved by FDA

Published Online: Thursday, August 30th, 2018
Officials with the FDA have approved Bayer’s antihemophilic factor [recombinant] PEGylated-aucl, BAY94-9027 (Jivi), for the routine prophylactic treatment of hemophilia A in previously treated adults and adolescents 12 years of age or older, according to the company.
 
BAY94-9027 is a recombinant factor VIII replacement therapy with a half-life of 17.9 hours. The initial recommended regimen is twice weekly (30-40 IU/kg), but dosing can be adjusted every 5 days (45-60 IU/kg) and can be further adjusted individually to less or more frequency based on bleeding episodes, according to Bayer.
 
The drug is also approved for on-demand treatment and the perioperative management of bleeding in the same population.
 
This approval is based on data from the 36-week phase 2/3 PROTECT VIII clinical trial, which included 126 previously treated patients 12 years or older with severe hemophilia A. Treatment with BAY94-9027 demonstrated bleed protection and safety of up to a median of 1.9 years. The drug was well tolerated in the majority of adult and adolescent patients. 
 
“As a physician who treats hemophilia A patients with a range of individualized needs, Jivi’s approved dosing allows me to adjust frequency based on their bleed episodes to maintain protection from bleeds, which is a serious concern among patients,” lead trial investigator Mark Reding, MD, associate professor of medicine at the University of Minnesota, said in a prepared statement.
 
The most commonly reported adverse effects in the trial were headache, cough, nausea, and fever. A FVIII inhibitor (1.7 BU/mL) was reported in one previously treated adult subject. Repeat testing did not confirm the presence of a FVIII inhibitor.
 
BAY94-9027 is Bayer’s third FDA-approved hemophilia A treatment, according to the press release.
 

Reference
 
Bayer Receives FDA for Jivi, New Hemophilia A Treatment With Step-Wise Prophylaxis Dosing Regimen [news release]. Bayer’s website. https://www.bayer.us/en/newsroom/press-releases/article/?id=123236. Accessed August 30, 2018. 

Current Issue

The Educated Patient

Jennifer L. Hofmann, MS, PA-C
Providing them with advice can improve control of the disease and reduce hospitalizations, morbidity, and unscheduled health care visits.
Emily C. Hayes, PharmD Candidate
Colds, coughs, and a relentless influx of sick patients in retail health clinics keep the health care providers who work there very busy.
Kristen Marjama, DNP, APRN-BC
Although the rate of foot and leg amputation has greatly declined over the past 2 decades, increasing awareness for macrovascular and microvascular complications of diabetes is essential because diabetes is the leading cause of lower-limb amputations in the United States.
Kristen Marjama, DNP, FNP-BC
Gluten proteins found in barley, rye, and wheat trigger systemic injury primarily to the small intestine, but they can also affect the joints, liver, skin, uterus, and other organs.
$vacMongoViewPlus$ $vAR$
Contemporary Clinic
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
ONCLive
OTCGuide
Pharmacy Times
Specialty Pharmacy Times
Targeted Oncology
About Us
Advertise
Careers
Contact Us
Feedback
Privacy
Terms & Conditions
Pharmacy Healthcare & Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-257-0701

Copyright Contemporary Clinic 2018
Pharmacy Healthcare & Communications, LLC. All Rights Reserved.